$SNPS

Synopsys Prediction: Analysts See 25% Upside After Q3 Beat and Raised Guidance

Synopsys reported Q3 FY2026 revenue of $2.48B, up 42.4% YoY, and raised full-year guidance. Analysts at 24/7 Wall St. predict a 25% upside to $496.97, citing strong fundamentals and AI-driven growth. However, shares are down 15.45% YTD due to China-related challenges and high valuation.

Original reporting
Published Sep 12, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 4:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SNPS
Bullish
high confidence
Mentioned
$SNPS
Relevance
8/10
AlphAI data visualization · based on kobaran.com
Decision brief

The 30-second read

$SNPSBullishMed
01

Why it matters

The earnings beat and guidance lift suggest a re‑rating opportunity, but execution risk from China restrictions and integration costs remain.

02

Market read

Strong earnings and guidance could narrow the gap between price and analyst targets, influencing AI‑related tech stocks.

03

What to watch

High restructuring and amortization charges may pressure GAAP earnings despite non‑cash nature.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Synopsys' Q3 results and guidance raise come amid AI‑driven demand and ongoing Ansys integration.

Company-level read

Ticker impact

$SNPSBullishHigh confidence
Context

Synopsys reported Q3 FY2026 revenue of $2.48B and raised full-year guidance to $9.715B revenue and $15.07 EPS.

Expected impact

Potential upside of 15‑25% if market digests the guidance lift.

Evidence & confidence

Guidance raise and strong revenue growth address prior price lag, aligning with analyst buy models.

Market effects

Highlights AI‑driven demand in EDA and simulation, supporting sector peers.

U.S. tech sector may see modest lift; China exposure remains a risk.

Reinforces broader AI‑related growth narrative across markets.

Counterpoint

China export controls could dampen near‑term demand, limiting upside.

Key entities

  • Synopsys

    EDA software provider reporting Q3 results.

  • Ansys

    Acquired firm whose integration drives future synergies.

Related articles

$SNPSMed

SNPS Upgraded by Morgan Stanley -- Price Target Maintained at $5

Morgan Stanley upgraded Synopsys (SNPS) to Overweight, maintaining a $500 price target. The stock is trading at $396.11, which is 39.9% undervalued according to its GF Value™ of $659.20. Synopsys has a GF Score™ of 88/100, indicating strong growth potential but concerns about valuation. Insider activity shows significant selling, with $40.7 million in sales over the last three months.

$SNPSMedAI 9/10

How to Play SNPS Stock as Layoffs Hit Synopsys

Synopsys (SNPS) reported Q3 FY2026 earnings with revenue of $2.48B, up 42.4% YoY, and EPS of $3.91, beating estimates. The company raised its full-year outlook. Analysts maintain 'Buy' ratings with price targets up to $633, citing long-term growth potential in semiconductor design.

$SNPSMedAI 8/10

Synopsys Falls as Strong Results Fail to Clear a High Bar

Synopsys (SNPS) shares fell 5.9% after reporting Q3 revenue of $2.48B and EPS of $3.91, both above guidance. The company raised full-year targets to $9.715B revenue and $15.07 EPS, but investors reacted negatively due to modest outlook increases, restructuring costs, and acquisition-related expenses. Insider sales and mixed hedge fund activity were also noted.